<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686281</url>
  </required_header>
  <id_info>
    <org_study_id>GMC-252-1.02</org_study_id>
    <nct_id>NCT02686281</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled, Randomised, Two Part Study of the Safety and Pharmacokinetics of GMC-252 in A) Healthy Male Subjects, Including a Comparison of GMC-252 Dosing in the Fed and Fasted States ,and B) in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genmedica Therapeutics S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Simbec Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genmedica Therapeutics S.L.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the toxicity, tolerability and safety of single&#xD;
      ascending doses of GMC-252-L-Lysine Salt in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business reason&#xD;
  </why_stopped>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Serious and Non-Serious Adverse Events</measure>
    <time_frame>Over a 14 days period post dose</time_frame>
    <description>Physical status (Vital signs; 12-lead ECG; Urinalysis; Haematology and biochemistry)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal Concentration (Cmax)</measure>
    <time_frame>Over a 14 days period post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve</measure>
    <time_frame>Over a 14 days period post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort A (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo&#xD;
Interventions:&#xD;
Drug: GMC-252-L-Lysine Other: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending oral administrations of GMC-252-L-Lysine Salt and matching placebo&#xD;
Interventions:&#xD;
Drug: GMC-252-L-Lysine Other: Placebo&#xD;
The dose administered in Part A (fed) was based on the outcome of Part A (fasted).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMC-252-L-Lysine</intervention_name>
    <arm_group_label>Cohort A (Part A)</arm_group_label>
    <arm_group_label>Cohort B (Part A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort A (Part A)</arm_group_label>
    <arm_group_label>Cohort B (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) within the range of 18-35 kg/m2 inclusive. BMI = Body weight&#xD;
             (kg) / [Height (m)]2.&#xD;
&#xD;
          -  Diet: Able to eat standard food, no vegetarians.&#xD;
&#xD;
          -  Compliance: Understood and was willing, able and likely to comply with all study&#xD;
             procedures and restrictions.&#xD;
&#xD;
          -  Consent: Demonstrated understanding of the study and willingness to participate as&#xD;
             evidenced by voluntary written informed consent and had received a signed and dated&#xD;
             copy of the Informed Consent Form.&#xD;
&#xD;
          -  Had no known hypersensitivity to diflunisal, NAC (N-acetylcysteine) or other&#xD;
             non-steroidal anti-inflammatory drugs (NSAIDs).&#xD;
&#xD;
          -  Had no known peptic ulcer diseases.&#xD;
&#xD;
          -  Had an estimated creatinine (CREA) clearance ≥ 50 mL/min (Creatinine clearance was&#xD;
             calculated from the serum CREA value using the Cockroft &amp; Gault formula).&#xD;
&#xD;
          -  Had no history of heart failure or uncontrolled hypertension or other known overt&#xD;
             cardiovascular disease.&#xD;
&#xD;
          -  Had no history of 'Aspirin Triad' (chronic rhinosinusitis with polyps, severe asthma&#xD;
             and intolerance to aspirin or other NSAIDs).&#xD;
&#xD;
          -  Had no marked abnormality of liver tests before entry into the study.&#xD;
&#xD;
          -  Male subject willing to use an effective method of contraception, if applicable&#xD;
             (unless anatomically sterile or where abstaining from sexual intercourse was in line&#xD;
             with the preferred and usual lifestyle of the subject) from Day 1 until 3 months&#xD;
             afterwards.&#xD;
&#xD;
          -  Subject with no clinically significant abnormal serum biochemistry, haematology and&#xD;
             urine examination values at the Screening Visit.&#xD;
&#xD;
          -  Subject with a negative urinary drugs of abuse screen (a positive alcohol result could&#xD;
             have been repeated at the discretion of the Investigator).&#xD;
&#xD;
          -  Subject with negative human immunodeficiency virus (HIV) and Hepatitis B (Hep B) and&#xD;
             Hepatitis C (Hep C) results.&#xD;
&#xD;
          -  Subject with no clinically significant abnormalities in 12-lead ECG at the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Subject was available to complete the study (including all Follow-up Visits).&#xD;
&#xD;
          -  Subject satisfied a medical examiner about their fitness to participate in the study.&#xD;
&#xD;
          -  Subjects were non-smokers and non-alcohol drinkers or drank alcohol in moderation&#xD;
             (e.g. ≤ 14 units/week).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A clinically significant history of gastrointestinal disorder likely to influence drug&#xD;
             absorption.&#xD;
&#xD;
          -  Receipt of regular medication at the Screening Visit that may have had an impact on&#xD;
             the safety and objectives of the study (at the Investigator's discretion).&#xD;
&#xD;
          -  Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or&#xD;
             metabolic dysfunction.&#xD;
&#xD;
          -  A clinically significant history of previous allergy/sensitivity to GMC-252.&#xD;
&#xD;
          -  A clinically significant history of drug or alcohol abuse.&#xD;
&#xD;
          -  Inability to communicate well with the Investigator (i.e., language problem, poor&#xD;
             mental development or impaired cerebral function).&#xD;
&#xD;
          -  Participation in a New Chemical Entity clinical study within the previous 16 weeks or&#xD;
             a marketed drug clinical study within the previous 12 weeks. (N.B. washout period&#xD;
             between trials defined as the period of time elapsed between the last dose of the&#xD;
             previous study and the first dose of the next study).&#xD;
&#xD;
          -  Donation of 450 mL or more blood within the previous 12 weeks.&#xD;
&#xD;
          -  Receipt of any medication since the Screening Visit that may have had an impact on the&#xD;
             safety and objectives of the study (at the Investigator's discretion).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Febbraro, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simbec Research Ltd</name>
      <address>
        <city>Merthyr Tydfil</city>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

